O. Yu. Sosnina

O. Yu. Sosnina

Auto-generated profile, based on publicly available information

O. Yu. Sosnina

Submittal of Federal State Unitary Enterprise “Scientific and Production Association for Immunological Preparations “Microgen” of the Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2018 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
IFI. V. Feldblyum
I. V. Feldblyum
VRV. V. Romanenko
V. V. Romanenko
ANA. M. Nikolaeva
A. M. Nikolaeva
KSK. A. Subbotina
K. A. Subbotina
OSO. Yu. Sosnina
O. Yu. Sosnina
AAA. V. Ankudinova
A. V. Ankudinova
Aim. The aim of the study is evaluate of reactogenicity, safety and immunogenicity of the native combined vaccine DTaP-HepB+Hib. Materials and methods. Assessment of reactogenicity, safety and immunogenicity of the drug is investigated in a multicenter, comparative, randomized, simple-blind clinical trial of immunization of children 6 months (the comparator vaccine DTaP-HepB combined vaccine, Hiberix®). Results. The native combined vaccine DTaP-HepB+Hib is characterized by good tolerability, high safety profile and a pronounced immunogenicity. In terms of seroprotection, seroconversion and geometric mean titers of antibodies comparable to that used in Russia of vaccines DTP-HBV and Hiberix®. Conclusion. Vaccine DTaP-HepB+Hib can be recommended for registration in the territory of the Russian Federation for the prevention of pertussis, diphtheria, tetanus, hepatitis B and Hib-infection.

15 February 2020 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
OSO. Yu. Sosnina
O. Yu. Sosnina
ANA. M. Nikolaeva
A. M. Nikolaeva
TVT. V. Vyaznikova
T. V. Vyaznikova
IFI. V. Feldblum
I. V. Feldblum
KSK. A. Subbotina
K. A. Subbotina
A research objective - to study the possibility of using the ELISA Anti-K enzyme immunoassay system to evaluate anti-pertussis immunity. A comparative assessment of the content of co-crank antibodies in the blood serum of adults, pregnant women and children 6 years old in the agglutination test, in the test system “Anti-K ELISA” and test systems of foreign production was carried out. The “Anti-K” IFA test system makes it possible to detect the level of specific antibodies to both the whole cell and cell-free pertussis component of the vaccine at any stage of the vaccination cycle. This diagnostic test can be used to determine the tactics of immunization, and to assess population immunity.